Innovation – the Irish National Network for

Ovarian Cancer Collaboration



Mission

Integration of patient clinical management with cutting edge research to improve the diagnosis and treatment of ovarian cancer

The importance of this research

Ovarian cancer is the leading cause of death from gynaecological malignancy in the western world. Worldwide there are more than 225,000 new cases of ovarian cancer and 140,000 deaths each year. Ireland has one of the highest mortality rates in Europe from ovarian cancer, with over 350 women diagnosed annually, and 65% dying within 5 years of diagnosis. Ovarian cancer has remained the most challenging of all the gynaecological malignancies for two reasons. First, early-stage disease while having a good prognosis, cannot be detected easily as it is either asymptomatic or the symptoms are non-specific. Second, standard chemotherapy approaches such as paclitaxel and carboplatin often fail and patients develop recurrent chemoresistant disease.

In 2014, internationally recognised ovarian cancer clinical and scientific experts across Ireland came together to address the clinical challenges posed by ovarian cancer. **INNOVATION**-the **I**rish **N**ational **N**etwork for **Ova**rian Cancer Collabora**tion** was established with a mission to integrate patient clinical pathways with cutting edge research to improve diagnosis and treatment of ovarian cancer.
The consortium agreed to implement comprehensive longitudinal monitoring of all ovarian cancer patients in Ireland, with biobanking of tissue samples for detailed molecular interrogation of tumour evolution, currently DISCOVARY bioresource in TCD banking until funding secured. The advanced analysis of ovarian cancer epidemiology, genomic characterisations and clinical observations could lead to the development of novel therapeutic targets as well as make an impact on mortality of ovarian cancer and the cost effectiveness of treatment. This INNOVATION strategy will provide a paradigm for how a significant healthcare and economic impact could be made for other more prevalent tumours.

Who are we?

INNOVATION comprises internationally recognised ovarian cancer clinical and scientific experts. The consortium was established in 2014 to address the dreadful mortality associated with ovarian cancer. The mission of the consortium is to integrate patient clinical pathways with cutting edge research to improve diagnosis and treatment of ovarian cancer. The group aims to secure funding to create a national centre of excellence for ovarian cancer and has identified key priority research areas that have the potential to improve outcomes for ovarian cancer patients. The group intend to implement comprehensive longitudinal monitoring of all ovarian cancer patients in Ireland, with biobanking of tissue/blood samples for detailed molecular interrogation of tumour evolution. This will form the backbone for the various technologies to be applied.

The consortium cover a range of expertise integral to ovarian cancer clinical management and research including;

- Medical oncologists
- Gynaecological oncologists
- Radiologists
- Pathologists
- Geneticists
- Scientists with expertise in genomics, proteomics, glycosylation, epigenetics
- Molecular Biologists
- Biochemists
- Cell biologists
- Stem cell biologists
- Microbiologists specialising in cancer therapy using microbes
- Medical Ethics experts
- Mathematical modellers
- Pharmacoepidemiologists
- Bioinformaticians
- Clinical nurse specialists
- Patient advocacy groups and charities

Team members:

INNOVATION comprises internationally recognised ovarian cancer clinical and scientific experts.

Individuals

Feras	Abu Saadeh	Gynaecological Oncologist	St. James's Hospital
Mark	Bates	Scientist	Trinity College Dublin
Kathleen	Bennett	Pharmacoepidemiologist	Trinity College Dublin
William	Boyd	Gynaecological Oncologist	MMUH and Mater Private
Dolores	Cahill	Proteomics professor	University College Dublin
John	Coulter	Gynaecological Oncologist	Cork University Maternity Hospital
Mattia	Cremona	Scientist	Royal College of Surgeons Ireland
Tom	D'Arcy	Gynaecological Oncologist	CWIUH, SJH
Michael Joe	Duffy	Biochemist	St. Vincent's hospital/UCD
Radka	Fahey	Glycobiologist	NIBRT
Michael	Farrell	CNS Genetics	Mater Private and MMUH
Angela	Farrelly	Scientist	Royal College of Surgeons Ireland
Grainne	Flannelly	Gynaecological Oncologist	National Maternity Hospital,
Richard	Flavin	Histopathologist	St. James's Hospital
David	Gallagher	Geneticist/Medical Oncologist	Mater Private/MMUH/St.James's
Noreen	Gleeson	Gynaecological Oncologist	St. James's Hospital/TCD
Bryan	Hennessy	Medical Oncologist	RCSI/ Beaumont hospital
Matt	Hewitt	Gynaecological Oncologist	Cork University Maternity Hospital
Roshni	Kalachand	Medical oncologist	RCSI/ Beaumont hospital
Eugene	Kashdan	Mathematical modeller	University College Dublin
Mary	Keogan	Radiologist	St. James's hospital/Trinity College
Steven	Madden	Bioinformatician	University College Dublin
Cara	Martin	Molecular biologist	Trinity College Dublin
Mary	McCaffrey	Cell Biologist	University College Cork
Amanda	McCann	Scientist-epigenetics	University College Dublin
Yvonne	McGarry	Biochemist	Trinity College Dublin
Lucy	Norris	Scientist	Trinity College Dublin
Donal	O'Brien	Gynaecological Oncologist	St. Vincent's and National Maternity
Dearbhaile	O'Donnell	Medical Oncologist	St. James's Hospital and TCD
Sara	O'Kane	Scientist	University College Dublin
John	O'Leary	Pathologist	Trinity College Dublin, CWIUH, SJH
Michael	O'Leary	Gynaecological Oncologist	University Hospital Galway
Ciarán	Ó Riain	Histopathologist	St. James's Hospital
Sharon	O'Toole	Scientist	Trinity College Dublin
Stephen	Pennington	Proteomics	University College Dublin
Sine	Phelan	Histopathologist	University Hospital Galway
Pauline	Rudd	Glycobiologist	NIBRT
Orla	Sheils	Molecular pathology/Ethics	Trinity College Dublin
John	Stratton	Gynaecological Oncologist	University Hospital Waterford
Mark	Tangney	Microbiologist	Cork Cancer Research Centre
Tom	Walsh	Gynaecological Oncologist	MMUH and Mater Private

Organisations

Molecular Medicine Ireland
Irish Gynaecology Oncology Nurses Group (IGONG)
Ovacare
SOCK
Emer Casey Foundation
The Irish Cancer Society

Abbreviations

CWIUH (Coombe Womens and Infants University Hospital)
MMUH (Mater *Misericordiae University Hospital)*
NIBRT (National Institute for Bioprocessing Research and Training)
RCSI (Royal College of Surgeons in Ireland)
SJH (St. James's Hospital)
TCD (Trinity College Dublin)

Biographies of Members

Mark Bates, Researcher
(Coombe Women's and Infants University Hospital, & Trinity College)

Mark Bates gained his bachelor's degree (BSc Hons) in biomolecular science in 2012 from the Dublin Institute of technology (DIT), Ireland and began a PhD with Trinity College Dublin (TCD) in November 2012, entitled "a therapeutic roadmap for ovarian cancer using MyD88 and MAD2 as prognostic indicators", which is funded by the Royal City of Dublin Hospital Trust, the Emer Casey foundation and SOCK. The aim of Mark's project is to assess the in vitro relationship between these two biomarkers and determine whether they can be used in combination to predict patient chemoresponse in ovarian cancer patients. Mark participated in the UREKA(Undergraduate Research Experience & Knowledge Award) funded by SFI in 2010, was winner of the lab tech supplies prize in 2011 and graduated at the top of his class, with a first class honours degree. As part of Mark's PhD so far, he has contributed to a peer reviewed article entitled "The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer" and has had abstracts published at various national and international conferences.

Dr John Coulter, Gynaecological Oncologist
(Cork University Maternity Hospital)

Dr. John Coulter is a practicing Gynaecological Oncologist at The Cork University Maternity Hospital. A UCC graduate in 1989, he underwent general surgical training for 3 years and attained Fellowship of the Royal College of Surgeons in Ireland (FRCSI). After general training in Obstetrics and Gynaecology from 1993 to 1998 both in Cork and The Coombe Womens and Infants University Hospital, Dublin, he travelled to Australia and completed a 3 year RANZCOG Fellowship training scheme in Gynaecological Oncology and is a certified Gyanecological Oncologist (CGO). He is currently a consultant in Cork and is chairman of the Cork Gynaecological Oncology Group Multidisciplinary Team. He is a member of the National Cancer Control Program guideline committee on hereditary gynaecological cancers.

Mattia Cremona, PhD
(Royal College of Surgeons in Ireland)

Mattia Cremona completed his PhD in Molecular Medicine through Universita' degli Studi di Milano in 2009. During his career in the field of cancer research, he has worked in several research hospitals in Europe and the US. More recently, he has established the first Reverse

Phase protein Array Platform in Ireland at Royal College of Surgeons in Ireland (RCSI). Mattia Cremona has published peer-reviewed papers, in addition to review articles and book chapters. Dr Cremona's research involves using proteomic high-throughput approaches to study the status of the pathways of proteins inside cancer cells and to highlight changes with normal cells that could explain tumour development or predict responses to anti-cancer therapies.

Professor M J Duffy, Professor School of Medicine
(St. Vincent's Hospital and University College Dublin)

Professor Joe Duffy (BSc, PhD, FRCPath, FACB) is based St Vincent's University Hospital, Dublin and University College, Dublin, Ireland. Professor Duffy has a world reputation for his work on cancer research, especially in the area of tumor markers. He is a member of a number of International Expert Panels for preparing guidelines on the clinical use of tumor markers including the National Academy of Clinical Biochemistry (NACB) (USA) and the European Group on Tumor Markers (EGTM). One of his main contributions has been the development of a test for identifying patients with breast cancer who may not need chemotherapy. This test, which involves measurement of the urokinase plasminogen activator (uPA) marker, is now recommended for clinical use by several expert groups including the American Society of Clinical Oncology. In 2012, Professor Duffy was the recipient of the 2012 Abbott Award of the International Society of Oncology and BioMarkers. This award is made annually to investigators, world-wide who have made an outstanding contribution in the field of basic or clinical oncology. Other awards received by Professor Duffy include the St Luke's Medal Lecture and the Conway Review Medal Lecture of the Royal Academy of Medicine in Ireland and the National Committee for Biochemistry Award Medal Lecture of the Royal Irish Academy.

Dr Radka Fahey (Saldova), Scientist
NIBRT (The National Institute for Bioprocessing Research & Training)

Dr Fahey joined the GlycoScience group (PI Prof Pauline M Rudd) in May 2005 as a Research Assistant and defended her PhD at the Institute of Chemical Technology Prague in November 2007. She continued as a Postdoctoral Researcher working on cancer glycobiomarkers and glycan analysis and joined the EU FP7 funded project, GlycoHIT, in January 2011 (http://www.glycohit.eu/). GlycoHIT aims to develop and validate complementary and integrated technologies for glycomic analysis of serum in cancer glycobiomarker discovery, diagnostics and glycotherapeutic monitoring. Dr Fahey has been awarded an SFI Starting Investigator research grant (SIRG) for "Epigenetic regulation of glycosylation and the impact on chemoresistance in cancer" commencing October 2014. This project follows on from novel published findings demonstrating that changes in DNA methylation in ovarian cancer cells are concomitant with significant alterations in the

expression of key enzymes that form part of glycosylation. Epigenetic alterations, tumour hypoxia and glycosylation are integral aspects of carcinogenesis. Determining the mechanism of epigenetic regulation of glycosylation and the link with hypoxia and drug resistance will help to improve the treatment of cancer patients by evaluating drugs such as 5-AZA, which is already in clinical trials. Little is known about the impact of this treatment on cellular glycosylation and the ability of cancer cells to bypass apoptotic cell death mechanisms. Dr Fahey also leads a Disease research subgroup and her other interests include the development and utilisation of high-throughput technologies for N-glycan analysis, disease biomarker discovery in cancer and inflammatory diseases and glycan analysis of various samples.

Research Areas

- Epigenetic regulation of glycosylation and the impact on chemoresistance in cancer
- Disease biomarker discovery in various cancers including - ovarian, breast, lung, prostate, uveal, skin, colorectal and pancreatic and other diseases (AAT deficiency, CDG, Rhematoid Arthritis)
- Development and utilisation of high-throughput technologies for N-glycan analysis
- Glycan analysis (glycans from serum, cells and isolated glycoproteins)

PubMed publications:
http://www.ncbi.nlm.nih.gov/pubmed/?term=saldova+radka
Webpage: http://www.nibrt.ie/cat_principal_investigators.jsp?i=241

Michael Farrell, CNS Cancer Genetics
(Mater Private and Misericordiae University Hospital)

Michael Farrell (RGN, H. Dip. in Applied Science, B. Sc. in Computing, Grad. Dip. in Oncology Nursing & M. Sc. in Molecular Medicine) has worked full time in clinical cancer genetics for over 9 years and is a Clinical Nurse Specialist (CNS) in the Cancer Genetic Department in the Mater Private Hospital (MPH) and the Mater Misericordiae University Hospital (MMUH) working with Dr. David Gallagher Consultant Medical Oncologist and Clinical Geneticist. Prior to working on the Mater campus he worked as a Research Nurse in St. James's Hospital (SJH) with Professor Peter Daly.

Michael gave oral presentations at both National and International cancer conferences and was an invited speaker on two occasions to the Joint Belfast/Dublin Clinical Genetics meetings. His research interest is in Lynch syndrome and he has delivered Grand Rounds on "Screening for Lynch syndrome" in St. Vincent's University Hospital (SVUH) and presented at the Medical Case Conference at the MMUH on "Interpretation of mismatch repair (MMR) variants of uncertain significance". Michael is first author on 2 papers published in the journal Familial Cancer and has presented 5 poster abstracts as first author, one was selected for oral presentation at the Cancer Genomics Masterclass at the Institute of Molecular Medicine (IMM) and he has co-authored an additional 6 poster abstracts. He is a member of the International Society of Gastrointestinal Hereditary Tumours' (InSiGHT's) MMR Variant Classification committee and this group's paper on strategies for classification of mismatch repair (MMR) variants was published with Michael as a co-author in Nature Genetics in 2014. He has presented talks on various aspects of inherited predisposition to cancer at the

Irish Association for Nurses in Oncology (IANO) annual meeting on two occasions and the Breastcheck Annual Radiographer Study Day and has presented on "Future Developments in Clinical Cancer Genetics" to Oncology Consultants and Registrars in MMUH. Michael also supervises clinical teaching for graduate nursing students and provides lectures on cancer genetics at St. Luke's Hospital, SJH and the Institute of Molecular Medicine (IMM) in addition to ad hoc presentations to patient support and advocacy groups such as the Dublin Well Woman Centre, the Gary Kelly Support Centre and ARC house.

Dr Angela Farrelly, Scientist
(Royal College of Surgeons Ireland)

Angela Farrelly graduated from the University of Nevada with a PhD in Molecular Physiology and Pharmacology in 2004. When she returned to Ireland in 2005 she worked as Group Leader in Molecular Diabetes (RCSI/UCD). In this role she investigated cell survival pathway regulation in a cellular model of mature onset diabetes of the young (MODY3). From 2011 to present she has been working with Dr. Hennessy based in RCSI Beaumont. Current project includes investigating the sensitivity of a large panel of ovarian cancer cell line to chemotherapy agents and PARP inhibitors. She has recently graduated with a Postgraduate Certificate in Clinical Research.

Dr Richard Flavin, Consultant Histopathologist
(St. James's Hospital, Dublin)

Dr. Richard Flavin is a consultant histopathologist at St. James's Hospital. A graduate of University College Cork, he completed his Specialist training in Dublin in Histopathology. His MD and PhD theses were on the molecular biology of ovarian cancer. This was followed by a period working as a Senior Medical Scientist/ Associate Director at the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute in Boston. He returned to St. James's Hospital in 2012 where he has subspeciality interest in gynaecological pathology and molecular diagnostics. He also acts as Administrative Head of the Post-mortem service and is the Director of the Histopathology Biobank.

Richard J Flavin MD PhD FRCPath
Phone: 01 416 2997
Fax: 01 410 3514
Email: rflavin@stjames.ie

Dr David Gallagher, Medical Oncologist and Medical Geneticist
(Mater Misericordiae University Hospital and St. James's Hospital Dublin)

Dr. David Gallagher is a graduate of University College Dublin Medical School. He completed his Senior House Officer rotation on the Trinity College Dublin Medical Scheme, before gaining a place on the Irish medical oncology specialist registrar programme, and

working as an oncology registrar in St. James's and the Mater Misericordiae University Hospitals, Dublin. In 2006 he was awarded a scholarship by the Irish Society of Medical Oncology to complete his training in medical oncology at Memorial Sloan-Kettering Cancer Center (MSKCC), New York. Upon completion of this advanced fellowship in medical oncology in 2008, he was offered a position on the medical genetics fellowship programme run jointly by MSKCC and Weill-Cornell New York Presbyterian Hospital. He completed this in August 2010 and returned to Ireland to take up a position as a consultant medical oncologist and medical geneticist at The Mater Private Hospital, Dublin. He also runs a cancer genetics clinic in St. James's and the Mater Misericordaie University Hospitals, Dublin. Dr. Gallagher has both clinical and translational research interests and has published his work in a number of peer-reviewed journals including Cancer, Clinical Cancer Research and the Journal of Clinical Oncology. He was awarded an MSKCC Prevention and Population Research Award, an MSKCC Genitourinary Department Research Grant and two merit awards from the American Society of Clinical Oncology prior to returning to Dublin. He is an active Member of the Irish Clinical Oncology Research Group (ICORG) and a clinical trial Principal Investigator for the Mater Campus and St. James's Hospital.

Dr Noreen Gleeson, Gynaecological Oncologist
(St. James's Hospital, Dublin and Associate Professor Gynaecological Oncology, Trinity College Dublin)

Dr Noreen Gleeson (M.D., M.R.C.O.G.) graduated from the National University of Ireland (UCC) 1981, is a Member of Royal College Obstetricians & Gynaecologist (1986) and has a Diploma in Statistics (1989) and Doctor of Medicine (1991) from Trinity College Dublin. She undertook gynaecological oncology fellowship training at the University of South Florida 1991-3 and she has been working at St James's Hospital since 1996. She is director of the Gynaecological Oncology Fellowship RCOG Training Programme at SJH. Her major clinical interests are gynaecological cancer, complex and reconstructive pelvic surgery. Her laboratory based research is in thrombosis/ haemostasis and molecular aspects of gynaecological malignancy. Her published research profile is available on ResearchGate. Email: noreengleeson@dubgyn.org

Prof Bryan Hennessy, Medical Oncologist
(Beaumont Hospital Dublin and Our Lady of Lourdes, Drogheda and Royal College of Surgeons Ireland)

Prof Bryan T Hennessy gained his medical degree in 1997 from University College Dublin (UCD), Ireland. Prof Hennessy graduated from the Medical Oncology Fellowship Program at The University of Texas M. D. Anderson Cancer Center (MDACC) in 2006 and completed a post-doctoral degree in Medicine through UCD in 2008. Prof Hennessy was a faculty member in the Division of Cancer Medicine at MDACC between 2006 and 2009. Currently, Prof Hennessy is a Consultant Medical Oncologist in Beaumont Hospital, Dublin and Our Lady of Lourdes Hospital, Drogheda. He is also

Associate Professor at Royal College of Surgeons in Ireland (RCSI) and an Adjunct Professor in the Division of Cancer Medicine at MDACC. Prof Hennessy has published over 60 peer-reviewed papers, in addition to multiple review articles, book chapters and editorials, and has extensive experience in kinome and kinase signaling research and in clinical and translational research in breast and the gynaecologic cancers. Prof Hennessy has achieved several accolades and grants from various organizations including a merit award, a young investigator award (YIA) and a career development award (CDA) from the American Society of Clinical Oncology (ASCO). He has also been a co-principal investigator of two prestigious U.S. National Institutes of Health (NIH) SPORE (Specialized Programs of Research Excellence) award projects.

Dr Matt Hewitt, Gynaecological Oncologist
(Cork University Hospital, Cork)

Matt Hewitt graduated from Nottingham University in 1993. After completing his internship and basic specialist training in the Trent region, Matt undertook an MD in the School of Human Development at the University of Nottingham, investigating the aetiology of recurrent pregnancy loss. Matt completed registrar training in the Trent region before deciding upon a career in gynaecological oncology. He moved to St James Hospital, Leeds, in 2001 to undertake a three year sub-specialist raining programme. Matt was appointed as a consultant Gynaecological Oncologist at St James in 2006, but shortly after moved together with his wife Louise to Cork University Maternity Hospital where he is also clinical senior lecturer with the Department of Obstetrics and Gynaecology. He practises in Low risk pregnancy, General Gynaecology, Gynaecological Oncology and Colposcopy. Dr Hewitt is the former President of the British and Irish Association of Robotic Gynaecological Surgeons (BIARGS).

Dr Eugene Kashdan, Applied Mathematician
(School of Mathematical Sciences, University College Dublin)

Dr Eugene Kashdan graduated with PhD in Applied Mathematics from Tel Aviv University in 2004. He spent next two years as a postdoc at Brown University, Providence, RI, where his research interests gradually switched from computational electromagnetics and plasma physics towards mathematical biology, in particular, to cancer modelling and computer assisted diagnosis. Following a year spent at the University of Arizona, Tuscon, he moved back to Israel to work as a Research Scientist at Tel Aviv University and a Lecturer at Afeka – Academic College of Engineering, also in Tel Aviv. Before joining the faculty of the UCD School of Mathematical Sciences in 2013, Dr Kashdan has worked as a quantitative analyst and an R&D manager in the financial companies in the City of London. In UCD, Dr Kashdan continues his research in mathematical oncology with a special interest in modelling of bladder cancer development and progression and simulation and optimisation of bladder cancer therapies (thermotherapy and BCG). Dr Kashdan serves as a chair of the organising committee of the international

workshop “Mathematical Methods in Systems Biology” (Dublin, Ireland, 2015). He has authored and co-authored more than 30 papers published in the scientific journals and proceedings of the international conferences, co-edited a book “Mathematical methods and models in biomedicine” published by Springer in 2012 and filed two patent applications. He also regularly serves as a guest co-editor of the special issues of the journal Mathematical Biosciences and Engineering. Dr Kashdan’s approach to automatic analysis of genetic properties of living specimen from their phase-contrast and modulation-contrast microscopic images with an application to IVF became a basis of the Commercial Case Feasibility Support grant funded by the Enterprise Ireland.

Prof Mary Keogan, Radiologist
(St. James’s Hospital, Dublin, Coombe Women’s and Infants University Hospital and Trinity College Dublin)

Professor Mary Keogan B.A. Mod, M.B, M.A, MRCPI, FRCR completed her undergraduate medical training in Trinity College Dublin. She trained in Medicine at St James's Hospital Dublin before training in Radiology in Addenbrooke's Hospital, Cambridge, and University College London. She completed her fellowship training in Abdominal Imaging in Duke University Medical Centre, North Carolina, USA. She was appointed Attending Radiologist and Assistant Professor at Duke University and subsequently was appointed Attending Radiologist in the Beth Israel Deaconess Medical Centre Boston and Associate Professor of Radiology at Harvard Medical School. She is a Consultant Radiologist in St James's Hospital and the Coombe Women's Hospital and a Clinical Professor of Radiology in Trinity College Dublin. She is a fellow of the European Society of Abdominal Radiologists and is the lead radiologist in the St. James's Hospital Gynaecology Oncology MDT group.

Professor Mary W. McCaffrey, Associate Professor in Biochemistry
(Molecular Cell Biology Laboratory, School of Biochemistry & Cell Biology, Biosciences Institute, University College Cork)

Prof. Mary W. McCaffrey has concentrated her research focus on small G-proteins since completing her Ph.D on retroviral insertional mutagenesis of oncogenes in the Universtity of London, UK / Imperial Cancer Research Fund in 1987. Her initial post-Doctoral training was on the Rho GTPase, in the CNRS, Gif-sur-Yvette, France, followed by a further two years of training at the Pasteur Institute, Paris working on the then newly discovered Rab proteins. She established an independent research group, on her appointment as a Lecturer in Biochemistry in University College Cork in late 1991. The team focused on the identification of Rab11(Rab11a, Rab11b & Rab11c[aka Rab25]) effector proteins, leading to the identification of a new protein family - the Rab11-FIPs - amongst which is the novel Rab Coupling Protein(RCP). Rab25 and RCP are both associated with aggressive breast and ovarian cancers. In our research, we seek to understand the molecular, cellular and physiological mechanisms by which Rabs and their modulatory proteins drive cancer aggressiveness.

Dr Amanda McCann, Senior lecturer
(School of Medicine, University College Dublin)

Dr McCann's research focuses on the mechanisms underlying Paclitaxel (Taxol®) chemoresistance for women presenting with epithelial ovarian cancer (EOC) and Triple Negative Breast Cancer (TNBC); specifically the spindle assembly checkpoint protein MAD2 through which Paclitaxel exerts its apoptotic affect. Epigenetically, the group are also interested in profiling DNA methylation and histone modification signatures in hypoxia and how this relates to ultimate chemoresistance and the retention of cellular viability (senescence/ autophagy) in the face of chemotherapeutic engagement.

Dr Stephen Madden, Research Fellow
(BREAST-PREDICT, University College Dublin, Ireland)

Dr Stephen Madden gained his Degree in Genetics in 1999 from Trinity College Dublin, Ireland. He graduated from University of York, UK, with a Masters in bioinformatics followed by a PhD in bioinformatics from University College Dublin (UCD) Ireland which was conferred in June 2007. After completion of his PhD Dr Madden worked as a postdoctoral researcher in bioinformatics and biostatistics for Molecular Therapeutics in Cancer Ireland, a Science Foundation Ireland funded Strategic Research Cluster with aims of discovering and developing new anti-cancer drugs. Currently, Dr Madden is a bioinformatics/biostatistics research fellow working as part of the Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT, a country-wide collaboration between experts in the area of breast cancer research. Dr Madden's career accomplishments to date include the publication of over 30 peer reviewed research articles in high impact journals such as Cancer Discovery and Cancer Research, contributing to a number of successful research grants and over 40 conference proceedings. This work has resulted in almost a 1,000 citations. Dr Madden's expertise in bioinformatics and biostatistics has allowed him to research and publish in numerous diseases such as ovarian cancer, breast cancer and diabetes.

Dr. Yvonne McGarry-Groarke, Research Biochemist
(Trinity College Dublin)

Dr. Yvonne McGarry-Groarke developed a novel monoclonal antibody to ovarian cancer cells while working at Athlone Institute of Technology (AIT) and was subsequently awarded a PhD. by Trinity College Dublin. She was honoured at a special award ceremony for her contribution to research at the institute. Yvonne later initiated follow-on cancer research in AIT, which involved postgraduate and research assistant supervision, and collaboration with the University of Pennsylvania, USA, Dublin City University, The Mater Misercordiae Hospital and Holles Street National Maternity Hospital in Dublin. During her time with AIT, Yvonne also lectured in the Toxicology Department. A graduate of NUI

Galway, Yvonne initially worked in food science research in University College Dublin and subsequently moved to the Nuclear Medicine department in St. Vincent's University Hospital as a clinical biochemist. The department was pioneering cancer research in Ireland at that time and was one of the first to offer a range of tumour markers for monitoring cancer patients and their treatment. She has also worked in the Nuclear Medicine Department at the Inselspital, Bern, Switzerland. Yvonne has a Masters Degree in Nuclear Medicine from UCD. Dr. McGarry-Groarke is currently involved in research utilising her unique antibody for ovarian cancer with St James's Hospital in Dublin.

Dr Lucy Norris, Senior Scientist
(Department of Obstetrics and Gynaecology, Trinity College Dublin)

Lucy Norris is a Senior Scientist in the Dept of Obstetrics and Gynaecology, Trinity College Dublin. She graduated with an honours degree Biochemistry at TCD and went on to obtain a PhD in the Dept of Obstetrics and Gynaecology in 1992 for her work on platelet activation in pregnancy and oral contraception. In 2002, she was awarded an MSc in Molecular Medicine from TCD and following this has established a group investigating the molecular aspects of coagulation activation in hormone users. Since then this has expanded to include studies in pregnancy and gynaecological cancers. She has over 20 years' experience in the area of haemostasis and thrombosis research and has published extensively on topics including the pathogenesis of thrombosis in hormone users, the role of coagulation and fibrinolysis in pregnancy and pre-eclampsia and more recently on the pathogenesis of venous thrombosis in gynaecological cancers. Current research includes the development of a risk model for prediction of venous thrombosis in gynaecological cancer patients funded by the HRB. She has over 50 peer reviewed publications, many as senior author, including 5 invited reviews. She is a member of the International Society for Thrombosis and Haemostasis and is a member of the editorial board for the journal 'Thrombosis Research'.

Prof John O'Leary, Pathologist
(Trinity College Dublin, St. James's Hospital and Coombe Women and Infants University Hospital, Dublin)

Professor John O'Leary holds the positions of Professor/Chair of Pathology, Trinity College Dublin, Director of Pathology, The Coombe Women and Infants University Hospital, Dublin, and Consultant Histopathologist, St. James' Hospital, Dublin, Ireland. His consultant diagnostic experience includes Gynaecological pathology, Breast pathology, Gastrointestinal pathology, Molecular diagnostic pathology and Cytopathology. Prof. John O'Leary heads a multi-investigator group of 40 scientists at TCD focused on the molecular characterisation of several cancer systems including:

Ovary, cervix, prostate, thyroid and head and neck cancer and cancer stem cell biology and the diagnosis of paediatric infections. In addition, the laboratory has a significant international reputation in the area of pregnancy proteomics and transcriptomics. His laboratory is a European reference centre for Applied Biosystems and Affymetrix and holds significant grant income from national and international sources including EU6th FP, EU7th FP, HRB, Irish Cancer Society and several foundations including the Emer Casey Foundation (dedicated to ovarian and uterine research). The individual groups are focussed on using functional genomics to understand the causes and molecular basis of the development of disease, with particular reference to cancer and cancer related systems. Projects include Cerviva (The Irish Cervical Screening Research Consortium – ICSRC) – A consortium of researchers dedicated to performing high quality research with a view to better understanding cervical cancer and how it develops and delivering the best possible information and guidance to support cervical screening services for women and DISCOVARY- A consortium of international researchers which was formed to specifically address issues in relation to ovarian and endometrial cancer diagnostics and prognostics and supports the development of translational research in Ireland. DISCOVARY has now merged with INNOVATION- the Irish National Network for Ovarian Cancer Collaboration. Prof O'Leary has a h-index of 40 and in excess of 7,000 citations. He has published in excess of 190 peer reviewed papers and in excess of 400 publications and is seated editor on three books. He recently received a Life Achievement award for Cancer Research at the RNAi 2011 International conference at Oxford University.

Dr Michael O'Leary, Gynaecological Oncologist
(University College Hospital, Galway)

Dr Michael O'Leary is a consultant Obstetrician and Gynaecologist with a subspecialty interest in Womens' cancers. He has worked at University College Hospital, Galway since 2009. He obtained his Diploma in Gynaecological Oncology from the Royal Australian and New Zealand College of Obstetricians and Gynaecologists in 2007. He is lead Colposcopist in the Galway CervicalCheck Clinic and is also the National Gynaecological Oncology Advisor to the National Cancer Control Programme.

Dr. Ciarán Ó Riain, Pathologist
(St. James's Hospital, Dublin)

Dr. Ciarán Ó Riain (MB Bch BAO PhD FRCPath) is a consultant histopathologist at St. James's Hospital. He is the lead histopathologist on the Gynaecological Oncology multidisciplinary team. A graduate of University College Dublin, he undertook his specialist histopathology training on the Dublin South training scheme. He commenced a Cancer Research UK Clinical Research PhD Fellowship at Barts Cancer Institute in London in 2007 and was awarded a PhD from the University of London in 2011 for his studies of the molecular biology of lymphoma. Prior to commencing at St.

James's Hospital in 2013, he spent time at internationally renowned centres of gynaecological pathology in Boston, Sheffield and Belfast. He is a member of ICORG (All Ireland Cooperative Oncology Research Group) and participated in the inaugural Ovarian Cancer Forum of Ireland.

Sharon O'Toole, Senior Research Fellow
(Trinity College Dublin)

Sharon O'Toole is a senior research fellow in Trinity College Dublin working in the area of ovarian cancer. She qualified with a BSc Hons in UCG in 1994 and then completed an MSc Biotechnology in 1996. Having worked in industry she then returned to research and completed a PhD in Trinity College in 2003. She has gained enormous experience in the area of ovarian cancer and has played a major role in the development of studies in gynaecological cancer. She was instrumental in establishing the DISCOVARY consortium which is a multidisciplinary and trans- institutional consortium dedicated to addressing the problems of ovarian and uterine cancer. The consortium manages the largest ovarian cancer bioresource in the country. She has been instrumental in establishing INNOVATION- the Irish National Network for Ovarian Cancer Collaboration which has brought together the medical, research and charity organisations involved in ovarian cancer in Ireland.

Her research interests centre around diagnostic and prognostic biomarkers and understanding the fundamental biology of the metastatic cascade and circulating tumour cells. She has been successful in identifying diagnostic and prognostic biomarkers for ovarian cancer and her ultimate aim is to translate these into the clinic. She has presented at both national and international conferences and published in peer-reviewed journals. She works closely with the 3 ovarian cancer charities in Ireland whose mission is to improve outcomes for ovarian cancer in Ireland. She was part of the organising committee of the first World Ovarian Cancer Day on May 8th in 2013 and this has now become an annual event.

Steve Pennington, Professor of Proteomics
(School of Medicine and Medical Science, UCD Conway Institute)

Steve graduated from Imperial College of Science and Technology, University of London with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge. During his PhD he was awarded an Elmore Medical Research Fellowship and it was during this fellowship that his interests in the regulation of the mammalian cell cycle began. He was Wellcome Lecturer in the University of Liverpool before moving to Dublin where he is currently Professor of Proteomics in UCD. His research team (www.biomedicalproteomics.org) use a range of proteomics platforms to identify pathogenic mechanisms and biomarkers in oncology and inflammartory disease. Stephen has been awarded a Beit Memorial Fellowship and received a Sir Henry Wellcome

Commemorative Award for Innovative Research. He serves on the editorial boards of several journals, and is currenty vice-president of the British Society for Proteome Research, a general council member of the European Proteomics Association and lead organizer of the forthcoming annual congress of the Human Proteome Organisation - HUPO2017.

Dr. Sine Phelan, Histopathologist
(Consultant Histopathologist, University Hospital Galway and Honorary Senior lecturer, National University of Ireland Galway)

Dr. Sine Phelan gained her medical degree from University College Dublin in 2001 and went on to complete the a specialist histopathology training programme, working at a number of centres including St. Vincent's University Hospital and St. James's Hospital. She was admitted as a fellow of the Royal College of pathologists in 2008. She worked as special lecturer in pathology at UCD from 2008-2010 during which time she was awarded an MD for her thesis entitled "An exploration of mechanisms underlying chemoresistance – SAC proteins and Hypoxia". Dr. Phelan was appointed as Consultant Histopathologist at University Hospital Galway in 2010 and is currently the lead pathologist in Gynaecological pathology. She also has special interests in breast pathology and in biobanking. She has a number of peer reviewed publications in the area of chemoresistance in ovarian cancer.

Pauline M. Rudd, Research Professor of GlycoBiology
(University College Dublin and National Institute for BioProcessing Research and Training in Ireland (NIBRT))

Professor Pauline M. Rudd BSc, LRIC, MA (Oxon), PhD is the Research Professor of Glycobiology at University College, Dublin. She heads the GlycoSciences Research Group at the National Institute for BioProcessing Research and Training in Ireland (NIBRT). Professor Rudd obtained a BSc in Chemistry at the University of London and a PhD in Glycobiology at the Open University, UK. She was a member of the Oxford GBI for 25 years, and a University Reader. She was a Founding Scientist of Wessex Biochemicals (later Sigma London), Visiting Research Associate at TSRI, Visiting Professor at Fudan University PRC, Visiting Scientist at BGU, Israel and Erskine Visiting Fellow, Canterbury University, NZ. She is a Fellow of the RSM, Visiting Professor at St. George's Hospital, London, Adjunct Professor at NE University, Boston, NUI Galway and Trinity College Dublin. She is a VI at BTI, AStar, Singapore. In 2012 she received a Waters Global Innovation award in recognition of her innovative research contributions to Glycbiology. In 2014 she was awarded an Honorary doctorate at Gothenburg University for contributions to Glycoscience.

Dr Feras Abu Saadeh, Gynaecological Oncologist
(St. James's Hospital, Dublin and Trinity College Dublin)

Feras obtained his medical degree (MB ChB) in Sebha Medical University, Libya in 2000. He then completed 5 years of post graduate training in obstetrics and gynaecology in Maqased Hospital, Jerusalem, before arriving in Ireland in 2005. Since 2006 he has worked as Specialist Registrar in the major maternity hospitals in Ireland including Cork University Maternity Hospital, Galway University Hospital, Coombe Women's and Infants University hospital and the Rotunda hospital. In 2008, he was appointed as lecturer/registrar at Cork University Maternity Hospital where he played a significant role in undergraduate teaching and was involved in the establishment and first year of operation of the Robotic theatre. Working as a Specialist Registrar in the Gynaecological Oncology unit at St James's Hospital, he became interested in the research program run in collaboration with TCD Obstetrics and Gynaecology. He began investigating the role of the TF and TFPI in the pathogenesis of ovarian cancer and, using tissue from the ovarian cancer biobank, showed that TF and TFPI gene and protein expression are increased in tumours from patients with ovarian cancers compared to those with benign disease. The results of his work were presented at local and international meetings. In July 2011, Feras was appointed as Research Lecturer at the Department of Obstetrics and Gynaecology/ TCD where he extended his studies to investigate the prediction of venous thrombosis (VT) in gynaecological cancer patients. His research was published in international peer reviewed journals. Feras has an MD from Trinity College Dublin and he is an RCOG accredited subspecialist in gynaecology oncology. Since 2013, he is working as a consultant gynaecological oncologist at St. James's hospital, Dublin.

Professor Orla Sheils, Professor of Molecular Pathology and Director of Medical Ethics (Trinity College Dublin)

Professor Orla Sheils is Professor of Molecular Pathology and Director of Medical Ethics at Trinity College Dublin. She has a PhD in Molecular Pathology from Trinity College Dublin and a MA in Medical Law and Ethics from Kings College London. The underlying theme of her research is to understand the causes and molecular basis of the development of disease, with particular reference to cancer, and to apply this knowledge to improving disease prevention, detection, diagnosis, and treatment. Improving the outlook for cancer patients can only come from an understanding of basic molecular and cell biology. There has been a dramatic increase in knowledge of the molecular genetics of cancers over the last few years and already we have reached the point where this can be translated into clinical application. With increased understanding of the mechanics of disease progression comes a requirement for innovative methods to detect nuances of patient specific tumours to triage those most likely to benefit from particular chemotherapeutic approaches and to discriminate between individual prognostic outcomes. She has a particular interest in novel therapeutics including small molecule kinase inhibitors and their interplay with cellular components such as miRNAs. Translational research is the

common theme throughout Prof Sheils' research, linking identification of disease processes with targets for early disease detection or classification. She has been an independent investigator since 2001 and has supervised 10 students to PhD level. Her department currently has 25 students pursuing the degree of PhD by research. She works closely with industry bringing novel technologies and applications to the translational research setting. Prof Sheils chairs TCD's Faculty of Health Sciences Research Ethics Committee. The Faculty Research Ethics Committee (F.R.E.C.) reviews projects involving humans in a variety of research contexts. She has been responsible for the procurement of grants valued in excess of €35M during this time from national funding agencies such as S.F.I., HRB, ICS and HEA in addition to industrial support from Life technologies (AppliedBiosystems / Ambion/ Invitrogen), Affymetrix and Vysis. She has published >75 peer reviewed publications.

Dr John Stratton, Gynaecological Oncologist
(Waterford Regional Hospital, Waterford)

Dr Stratton is a gynaecological oncologist working in Waterford. He established and runs the gynaecological cancer and colposcopy services in Waterford Regional Hospital. He trained in gynaecological cancer surgery at Sheffield University Teaching Hospital and is an accreited subspecialist. His PhD thesis was undertaken in Cambridge on the genetic basis of ovarian cancer. During his time in Cambridge he trained in familial cancer genetics and he currently runs a clinic for women and their families who have a family history of breast and ovarian cancer. He has published extensively on all aspects of gynaecological cancer and in particular on ovarian cancer genetics. Current areas of interest include laparoscopic surgery, fertility sparing surgery and neoadjuvant therapy.

Mark Tangney BSc,PhD,MBA
(Cork Cancer Research Centre)

Mark is a Principal Investigator at the Cork Cancer Research Centre at University College Cork where his research group investigates cancer therapies using microbes. With a PhD in microbiology from UCC, his interests include study of the relationships between bacteria and cancer, and the development of tumour-specific drug delivery technology utilising bacteria or viruses. He has worked for a number of years at various international institutions (Los Angeles, Boston, Copenhagen) and has published extensively in the field of cancer therapy and microbiology. Mark is a member of the Executive Council of the International Society for Cell and Gene Therapy of Cancer (ISCGT), Vice-President of the Irish Society for Gene and Cell Therapy (ISGCT), a scientific committee member of the European Society for Gene & Cell Therapy (ESGCT), a council member of the Irish Association for Cancer Research (IACR) and a member of the editorial board of several international journals (Human Gene Therapy, Current Gene Therapy, Bioengineered, Biomarkers in Cancer). His group's work is funded by grants awarded from EU FP7, Health Research Board, Cancer Research Ireland, Science Foundation Ireland and Enterprise Ireland. Mark's group has joined forces with a large network of like-minded laboratories around the world and as a result, this collaborative research is advancing rapidly towards patient treatment.

Dr Tom Walsh, Gynaecological Oncologist
(Mater Misericordiae University Hospital, Dublin)

Dr Tom Walsh qualified from the Royal College of Surgeons in Ireland in 1996. He did his initial training in Obstetrics and Gynaecology at the Rotunda Hospital, National Maternity Hospital, St. Vincent's Hospital and Mater Misericordiae University Hospital Dublin. He has a wide range of interests in general Obstetrics and Gynaecology and holds a Certificate of Specialist Training (CST) in these areas. He is Sub-Specialty trained in Gynaecological cancers having completed a fellowship program in Gynaecological Oncology in Australia. He was awarded the internationally recognised Diploma in Gynaecological Oncology by The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Dr. Walsh is appointed as a consultant in the Rotunda Hospital and in the Mater Misericordiae University Hospital, Dublin.

Our Mission

To improve diagnosis and education of ovarian cancer within Ireland, through sharing global research and best practice, and providing support and advocacy through OvaCare's dedicated support network.

Who we are- Our Founders

OvaCare was co-founded by June Feeney and Rachel Ireland in 2011, following their own personal experiences with ovarian cancer. They both felt there was very little support in Ireland for women and their families affected by the disease, and they believe strongly that OvaCare can help provide this support as well as 'giving a voice' to the disease. Our medical panel, led by Senior Scientist Dr Sharon O'Toole from Trinity College; consists of Gynaecological Oncologists from each of the 8 Centres of Excellence, Medical Oncologists, Pathologist, Medical Geneticist, Epidemiologist, Medical Social Worker, Gynaecological Nurse Specialists and the Director of Women's Health at the ICGP.

What we do

Support -Patient Days and support groups

Patient Days have taken place in Cork and Dublin which provide information and support for ovarian cancer patients and their families. It provides the opportunity to hear from leading clinicians, therapists and researchers specialising in the disease, as well as being a chance to meet fellow patients. The response to these days has been astounding; with many patients stating that they 'no longer feel alone'. We are currently in the process of establishing ovarian cancer support groups. From our Patient Days it is clear that women would appreciate the opportunity to meet with others going through similar experiences on a regular basis for support and encouragement.

Information

Our website www.ovacare.com provides vital factsheets on ovarian cancer, the latest news, clinical trial updates and progress in research as well as information on upcoming events.

Online Community

Our online community forms part of our website and is a place where patients and family members share their experiences, fears, hopes and concerns via online blogs, questions and polls. The community is proving a valuable resource for those directly affected by a disease which sees over 300 new diagnoses each year in Ireland.

Advocacy

OvaCare is a member of ENGAGe (European Network of Gynaecological Cancer Advocacy Groups) which is a subgroup of ESGO (European Society of Gynaecological Oncology). We are also members of ECPC (European Cancer Patient Coalition) and IPPOSI (Irish Platform of Patient Organisations, Science and Industry).

Our own members of OvaCare, who are primarily patients and family members, continually express concern that their cause is little known in Ireland and therefore little understood or provided for. In addressing the former issue of being little known, OvaCare was actively involved in establishing the first every World Ovarian Cancer Day and was part of the International working group rolling this out on May 8th 2013. In relation to the latter issue of provision, OvaCare is working with the Emer Casey Foundation and SOCK to bring about improved GP access to ultrasound, which is essential in establishing timely diagnosis and subsequent earlier treatment.

CHY17505

www.emercaseyfoundation.com

Introduction and Background

The Foundation was established in 2006 following the death of Emer Casey. Emer was the youngest of a family of five daughters and she had just recently qualified as a solicitor at Matheson Solicitors in Dublin when she became ill. She was diagnosed with ovarian/endometrial cancer in February 2006 and she died on June 10th 2006 aged only 28. Since then Emer's family, friends and work colleagues at Matheson Solicitors have been working on behalf of the Foundation. To date the Foundation has raised in excess of €700,000.

The Emer Casey Foundation is continuing its work in the areas of research, patient care and consciousness raising. In September 2013, The Emer Casey Foundation hosted the Emer Casey Symposium at the inaugural Ovarian Cancer Forum of Ireland in Barberstown Castle, Kildare. Three leading professors from the research projects that benefit from Foundation funding presented their findings at the Symposium. Professor O' Leary from the Dublin-based DISCOVARY consortium was joined by Professor Charlie Gourley (Edinburgh) and Professor Ian Campbell (Melbourne). Two months later, in November, three Emer Casey Fellows graduated with their doctoral theses from Trinity College, Dublin. An agreement is in place to fund a fourth Emer Casey Fellow who will continue to work on the significance of novel proteins that appear to predict the presence of ovarian cancer. The Emer Casey Foundation funded the first Gynaecological Oncology Liaison Nurse Specialist at Cork University Maternity Hospital for a one year period. The HSE has now taken over the funding of this position on a permanent basis.

Twitter: @EmerCaseyFndtn
www.emercaseyfoundation.com

Supporting **O**varian **C**ancer **K**nowledge (SOCK) was the brainchild of the late Jane Keating. Following her diagnosis with ovarian cancer at the young age of 28, Jane wanted to do something positive as there was limited information available to women about ovarian cancer. Jane approached a number of her friends and family from the Blanchardstown area and suggested that a charity be formed. **S**upporting **O**varian **C**ancer **K**nowledge (SOCK) was founded in 2010, our charity number is CHY19231. SOCK it is a non-profit organisation and is dedicated to raising funds for research into and awareness of ovarian cancer.

The SOCK Committee became aware that there are leaflets in doctors' surgeries in relation to breast cancer, lung cancer, cervical cancer, prostate cancer etc., however, not for ovarian cancer. We decided that SOCK would change this. Our first initiative was to develop an information leaflet which highlights the symptoms of ovarian cancer and promote awareness of this cancer. Our leaflet has been endorsed by Consultant Medical Oncologist Paula Calvert, (Waterford Regional Hospital & Whitfield Clinic). This awareness campaign is well underway with our information leaflets available in doctors' surgeries throughout Ireland. Our slogan is to ***Know your body, Know the symptoms*** – because the symptoms of ovarian cancer can be very vague and they often appear at a late stage. In order to ensure this campaign continues and that we can develop this in the future we need to continue fundraising. For more information & to view our information leaflet please visit our website www.sock.ie

SOCK is part funding a Research Co-Ordinator post in the Cancer Clinical Trials Unit in Waterford Regional Hospital. This is enabling research into ovarian cancer and assisting in the roll out of medical trials to ovarian cancer patients. To date it has enabled the roll out of the ICON8 trail to ovarian cancer patients in the south-east. In addition, SOCK recently provided €20,000 funding to Ovarian Cancer Research in Trinity / St James's Hospital.

In light of recent media coverage in relation to charities, SOCK would like to confirm that all members volunteer their time to the charity. No wages or bonus payments are given to members. 100% of donations go directly towards ovarian cancer.

Like us on Facebook: Supporting Ovarian Cancer Knowledge

Follow us on Twitter: @SOCKCharity

CHY: 19231 | info@sock.ie | www.sock.ie
✉ 44 Glenville Drive, Blanchardstown, Dublin 15 ☎*086 3472804*

Collaborative Funding to date:

Many members of the group have been collaborating prior to the formal establishment of INNOVATION and have secured funding from the Health Research Board, Science Foundation Ireland, the Royal City of Dublin Hospital Trust, the Emer Casey Foundation, SOCK and Fujirebio Diagnostics. Examples of recent projects include;

- What is the circulating tumour cell and the role of the immune editing in the metastatic cascade?
- Oncology 1 strand of the Biomedical Diagnostics Institute - Dublin City University
- A risk model for prediction of venous thromboembolism in gynaecological cancer patients post surgery
- Interrogation of the onco-metabolome in ovarian cancer
- Evaluation of the half life of HE4 in optimally debulked epithelial ovarian cancer patients
- A therapeutic roadmap for ovarian cancer using MyD88 and MAD2 as prognostic indicators
- Epigenetic regulation of glycosylation and the impact on chemoresistance in cancer

Collaborators

International Consortia

Cancer Trials Ireland
Centre for Cancer Research & Cell Biology, Queens University, Belfast.
The European Network of Translational Research in Gynaecological Oncology (ENTRIGO)

Individuals

Prof. Gordon Mills, MD Anderson, Texas, USA
Dr. Maurie Markman, Cancer Treatment Centers of America
Prof Linda Sharp, University of Newcastle, UK
Prof Lance Liotta, George Mason University, USA
Prof Chip Petricoin, George Mason University, USA
Dr Britta Stordal, Middlesex University, UK
Prof Doug Brooks, University of Adelaide, Australia, Visiting Professor TCD
Prof Stavros Selemidis, RMIT University, Melbourne, Australia
Prof Ken O'Byrne, Professor, Queensland University of Technology
Dr Marion Butler, Maynooth University

Industry Collaborators

Abbott Laboratories

Adnagen AG

Affymetrix Inc.

Agilent Technologies

Almac Group Ltd.

Cellix Ltd.

Fujirebio Diagnostics Inc.

GE Healthcare

Genentech Inc. (Roche)

Greiner Bio-one Inc.

GlaxoSmithKline Plc.

Illumina Inc.

Johnson and Johnson

Leo Laboratories Ltd.

Life Technologies Inc.

Lonza Group

Myriad

Novartis AG

Oncomark Ltd.

Opsona Therapeutics Ltd.

Qiagen Ltd.

Raman Diagnostics Ltd.

Randox Laboratories Ltd.

Roche

ScreenCell

Further Information:

Dr Sharon O'Toole
Department of Obstetrics and Gynaecology
Trinity Centre for Health Sciences
St. James's Hospital
Dublin 8.

Phone:+35318962106
Email: shotoole@tcd.ie
http://medicine.tcd.ie/obstetrics-gynaecology/

Prof John O'Leary
Department of Histopathology
Trinity College Dublin
Sir Patrick Dun Research Laboratory
St. James's Hospital
Dublin 8.

Phone: +35318963296
Email: olearyjj@tcd.ie
http://medicine.tcd.ie/histopathology/